The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Want a say in the news? Email Claudia at [email protected] to have your thoughts on the stories covered here or on ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

While it's next to impossible to know how many opioids entered the state illegally in 2023, we do know that just under 1.7 ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.